Trial Information
Inclusion Criteria:
- Patients who participated on UMCC 9900/9901
- Living patients must give written informed consent
Exclusion Criteria:
- No tumor block tissue available
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Principal Investigator
Anne F. Schott, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Michigan Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
UMCC 3-27
NCT ID:
NCT00146029
Start Date:
Completion Date:
Related Keywords:
- Metastatic Breast Cancer
- Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)
- Breast Neoplasms
Name | Location |
University of Michigan Cancer Center |
Ann Arbor, Michigan 48109 |